[Management of prolactinomas during pregnancy].
OBJECTIVE
To evaluate the safety of discontinuing drugs for prolactinoma during pregnancy, and the effect of prolactinoma on pregnancy.


METHODS
Thirty-two cases of prolactinoma in pregnancy were enrolled, 22 microadenoma and 10 macroadenoma.


RESULTS
Adenoma growing appeared in 6 cases. Among them 5 were macroadenoma, dopamine agonists were then reused and surgery were carried out in 2 of them. The other was one microadenoma, dopamine agonists was reinstituted. No side effect on fetus's weight and appearance was seen. Gestation complication was as normal.


CONCLUSIONS
Discontinuing dopamine agonists is safe during pregnancy for microadenoma. The risk of macroadenoma enlargement during pregnancy is high. Regular visal field testing is necessary during pregnancy. Prolactinoma doesn't influence gestation complication and fetus.
Chen
Weilin
W
Department of Obsterics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences  Beijing 100730  China.
Bian
Xuming
X
Gai
Mingying
M
Zhang
Yiwen
Y
D000236:Adenoma / Q000150:complications / Q000628:therapy*; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000209:etiology; D010911:Pituitary Neoplasms / Q000150:complications / Q000628:therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000628:therapy*; D011256:Pregnancy Outcome; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000150:complications / Q000628:therapy*; D012189:Retrospective Studies
D018491:Dopamine Agonists; D001971:Bromocriptine; D011388:Prolactin